海隆控股(01623.HK):票據違約 鼓勵持有人加入臨委會商解決方案
海隆控股(01623.HK)公布,2020年現有票據於6月22日到期,由於並無可替代的融資途徑償還現有票據,導致對2022年票據交叉違約,目前正在評估上述違約對其其他債務的影響,指出目前尚未收到任何加速2022年票據的要求,亦無收到要求立即償還其他債項下的債務的任何通知。
為促成解決方案,該公司委聘鐘港資本及盛德律師事務所為財務顧問與法律顧問。
公司鼓勵現有票據及2022年票據的持有人考慮加入臨時委員會。海隆控股現正開始並擬及時與現有票據及2022年票據的持有人展開透明對話,以求識別及實施適當考慮所有利益相關者情況的一致共識的解決方案。公司將就該等事項的進度及時告知市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.